FMP
Verona Pharma plc
VRNA
NASDAQ
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.
42.02 USD
0.8 (1.9%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Dr. David S. Zaccardelli Pharm.D.
sector
Healthcare
industry
Biotechnology
website
https://www.veronapharma.comexchange
NASDAQ
Description
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in...
CIK
0001657312
ISIN
US9250501064
CUSIP
925050106
Address
3 More London Riverside
Phone
44 20 3283 4200
Country
GB
Employee
79
IPO Date
Apr 28, 2017
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
VRNA Financial Summary
CIK
0001657312
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
925050106
ISIN
US9250501064
Country
GB
Price
42.02
Beta
0.42
Volume Avg.
1.01M
Market Cap
3.44B
Shares
-
52-Week
11.39-43.73
DCF
3.5
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-21.01
P/B
-
Website
https://www.veronapharma.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest VRNA News
It looks like there's no news available.
